VentureIsrael Appoints Evgenia Zaslavskaya as Venture Partner

TEL AVIV-YAFO, Israel, Sept. 23, 2026 /PRNewswire/ -- VentureIsrael, an Israeli venture capital fund investing in early-stage deep tech companies, announced the appointment of Evgenia Zaslavskaya as Venture Partner to lead international communications for the fund and serve as a communications resource for its portfolio companies.

Evgenia is a PR professional with more than 15 years of experience, and the founder and CEO of Zecomms, an international communications agency that works with tech companies and investment funds in the US, the UK, Europe, and the MENA region. In 2025, she was named Best Leader in Public Relations and Communications at the Davos Communications Awards.

Zaslavskaya has been managing VentureIsrael's public and media relations since 2022. The new appointment expands this collaboration and brings her directly into the fund's venture partner team.

"We've worked with Evgenia and her team for several years now and have seen first-hand how much strategic communications shape the way the market perceives a fund and the companies it backs. Bringing her into the venture partner team is a natural next step for us: we want this expertise inside the fund, available to every founder we support from day one. Evgenia understands both the venture market and Israeli deep tech, and that combination is exactly what we need right now to grow further," said Rafael Gold, Managing Partner at VentureIsrael.

Zaslavskaya's new role covers strategic communications for VentureIsrael. She'll make the fund's strategy, track record, and expertise visible to investors, partners, and customers in the US, the UK, and other key international markets. Her work will include positioning the fund in global markets, building relationships with business and tech media, growing the partners' public profiles, and shaping the news narrative around VentureIsrael and its portfolio. Founders in the portfolio will have access to the same expertise for their own technology, teams, and traction.

"Israel has a vibrant tech market with many products worth talking about, and I want to bring more of them to a global audience. Partnering with VentureIsrael—a firm I've worked with for many years, and one that has backed some of the country's most interesting deep-tech companies—is a natural place to do that," Zaslavskaya added.

About VentureIsrael

VentureIsrael invests in early-stage Israeli technology companies across AI, cybersecurity, space, quantum technologies, and other deep-tech segments. The fund is ranked the third most active venture capital investor in Israel. Its portfolio today includes more than 30 technology companies, and the team has completed 50+ investments and 10+ exits—both through the fund and in the partners' earlier investment activity.

About Zecomms

Zecomms is an international communications agency founded in 2022 by a seasoned PR professional Evgenia Zaslavskaya. The team works primarily with technology companies and investment and venture funds, helping them build visibility in the US, Europe, the UK, and MENA. The agency's portfolio includes dozens of notable projects in AI, cybersecurity, robotics, and health fields.

For more details contact

Lana Dikova, PR Manager at Zecomms

[email protected] 

SOURCE VentureIsrael

Share this article

OAKLAND, Calif., Sept. 23, 2026 /PRNewswire/ -- The Clorox Company (NYSE: CLX) announced today that its board of directors has declared a quarterly dividend of $1.25 per share on the company's common stock. The dividend is payable November 13, 2026, to shareholders of record as of the close of business on October 28, 2026.

Clorox has a long history of providing value to its shareholders through regular dividend payments and annual dividend increases.

About The Clorox Company

The Clorox Company (NYSE: CLX) champions people to be well and thrive every single day. Headquartered in Oakland, California since 1913, Clorox integrates sustainability into how it does business. Driven by consumer-centric innovation, the company is committed to delivering clearly superior experiences through its trusted brands including Brita®, Burt's Bees®, Clorox®, Fresh Step®, Glad®, Hidden Valley®, Kingsford®, Liquid-Plumr®, Pine-Sol® and Purell® as well as international brands such as Chux®, Clorinda® and Poett®. Visit thecloroxcompany.com to learn more.   

CLX-C

SOURCE The Clorox Company

Share this article

Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand

From equations and experiments in the laboratory to exclusive skincare for skin longevity

WILMINGTON, Del., Sept. 23, 2026 /PRNewswire/ -- Biophysical Therapeutics, a Delaware company, announces the launch of its consumer longevity brand called IF1.

It is currently accepting pre-orders for its first product, an anti-aging skin moisturizer available at www.IF1.skin. Only 500 units are available in the initial production run, retailing at $120 apiece.

This moisturizer is distinctive in incorporating leading-edge longevity science, and is further distinct, since the profit from its sales will feed back to fund the company's drug programs, which include drugs against cancer, age-related diseases (such as Alzheimer's disease), and aging itself.

The company was founded in 2022 by Dr. Michael Forrest, a Cambridge University biochemistry graduate with a Ph.D. in computer science, and is advised by Professor George Church of Harvard Medical School. Its specialty is computational biology and especially biophysical modeling, which is mathematical modeling of the physics and chemistry of a biological system, and the company is named after this approach. Unusually for a computational biology company, it has actually delivered new experimentally-validated drugs working as predicted in vivo, protected by granted patents.

The science behind the company's new anti-aging skin moisturizer is its conclusion regarding why different mammal species can have such different lifespans, for example, a mouse maximally lives 4 years whereas a bowhead whale can live centuries longer. This conclusion is complex but it distills to simplicity - species with more IF1 protein live longer. Indeed, the company has shown that increasing IF1 protein in mice reduces aging as measured by an aging biomarker.

People already buy anti-aging skincare. Indeed, it is already a $70B market and growing. This bodes well for this new brand that leverages differentiated anti-aging science from leading anti-aging scientists, which will in turn fund them to advance science and medicine. Economists calculate that the economic benefit of slower aging, to the USA alone, is $38T per year of increased life expectancy.

Dr. Forrest says: "Our IF1 brand brings leading-edge anti-aging science to skincare. This is just part of our mission to save, improve, and extend lives at mass scale."

The IF1 anti-aging skin moisturizer is available for pre-order now exclusively at www.IF1.skin.

About Biophysical Therapeutics

Biophysical Therapeutics is a Delaware-based biotechnology company that uses computational biology, especially biophysical modeling, to discover new fundamental biology and design new drugs. Its primary targets are cancer, the diseases of aging (e.g., Alzheimer's disease), and aging itself. The company has a pipeline of experimentally-validated new drugs and a portfolio of granted patents. It owns a longevity skincare brand called IF1, which is available at www.IF1.skin.

Contact:

Biophysical Therapeutics

***@biophysicaltherapeutics.com

Photo(s):

https://www.prlog.org/13171701

SOURCE Biophysical Therapeutics

Share this article

- Bangladesh Minister of Civil Aviation and Tourism M. Rashiduzzaman Millat

- State Minister of Foreign Affairs Humaiun Kobir

- Invest Bangladesh Authority Chairman Chowdhury Ashik Mahmud Bin Harun

- Advisor to the Prime Minister Madhi Amin

- U.S. Secretary of Commerce Howard Lutnick

- U.S. Deputy Secretary of State Christopher Landau

"Today's supplemental agreement is an important step in Biman's ongoing fleet renewal and network expansion. This order responds to specific requirements in our fleet plan. Our team's working relationship with Boeing over the years has given us confidence in the delivery and support arrangements," said Mr. Rumee A Hossain, chairman of Biman Bangladesh Airlines. "As the national flag carrier, we remain committed to developing Biman's network and capabilities in a manner that responds to the connectivity needs of the people of Bangladesh, our expatriate community, business and tourism. This agreement is one part of a broader, carefully considered plan to strengthen the country's international connectivity in the years ahead."

Biman currently operates 787, 777 and 737 Next‑Generation airplanes across its international network, connecting Bangladesh with major hubs in the Middle East, South and Southeast Asia, and Europe. The 787 Dreamliner and 737 MAX families deliver 20-25% more fuel efficiency compared to the airplanes they replace, supporting the airline's strategy to modernize its fleet and expand global connectivity.

"Biman's follow-on order reflects its strategic approach to fleet renewal and capacity growth, and underscores the strength of our long-standing partnership," said Brad McMullen, Boeing senior vice president of Commercial Sales and Marketing. "These additional 787 Dreamliner and 737 MAX airplanes will deliver the efficiency, versatility and reliability Biman needs to support Bangladesh's growing role in global aviation."

The addition of the 737‑8 and 787‑10 strengthens Biman's established Boeing fleet, ensuring seamless commonality across operations. The 737‑8 brings greater range to the airline's single‑aisle network, while the 787‑10 adds higher capacity to complement Biman's 787‑9 and 787‑8 airplanes.

A leading global aerospace company and top U.S. exporter, Boeing develops, manufactures and services commercial airplanes, defense products and space systems for customers in more than 150 countries. Our U.S. and global workforce and supplier base drive innovation, economic opportunity, sustainability and community impact. Boeing is committed to fostering a culture based on our core values of safety, quality and integrity.  

Contact

Siddhant Chauhan

Boeing India and South Asia Communications

[email protected]

Boeing Media Relations

[email protected]

SOURCE Boeing

Share this article

NCIG Announces Expiration and Results of Cash Tender Offer for Any and All of its Outstanding 4.400% Guaranteed Senior Secured Notes due 2027

NEWCASTLE, Australia, Sept. 23, 2026 /PRNewswire/ -- Newcastle Coal Infrastructure Group Pty Ltd (the "Company"), a direct wholly-owned subsidiary of NCIG Holdings Pty Ltd (the "Parent Guarantor"), announced today the expiration and results of its previously announced cash tender offer (the "Offer") for any and all of its outstanding 4.400% Guaranteed Senior Secured Notes due 2027 (the "Securities").

Expiration and Results

The Offer was made pursuant to the Offer to Purchase dated September 8, 2026 (the "Offer to Purchase") which sets forth a more detailed description of the Offer. The Offer expired at 5:00 p.m., New York City time, on September 23, 2026 (the "Expiration Date"). Withdrawal rights for the Securities expired at 5:00 p.m., New York City time, on September 23, 2026.

According to information provided by Global Bondholder Services Corporation, the tender and information agent for the Offer (the "Tender and Information Agent"), the aggregate principal amount of the Securities set forth in the table below under "Original Aggregate Principal Amount Tendered" had been validly tendered and not validly withdrawn in the Offer as of the Expiration Date.

The Company expects to accept for purchase all of the Securities validly tendered and not validly withdrawn at or prior to the Expiration Date. The Company urges the registered holders of the Securities (together, the "Holders" and each, a "Holder") to read the Offer to Purchase carefully before making any decision with respect to the Offer. The Offer to Purchase may be obtained by contacting the Tender and Information Agent using the telephone number or email address found below under "Dealer Managers and Tender and Information Agent."

Consideration and Accrued Interest

As previously announced, the Tender Offer Consideration (as defined in the Offer to Purchase) per original US$1,000 principal amount of Securities validly tendered and accepted for purchase is US$993.11, as determined at 3:00 p.m., New York City time, on September 23, 2026. The Settlement Date is expected to be September 28, 2026. In addition to the Total Consideration (as defined in the Offer to Purchase, being an amount equal to the product of (i) the original principal amount of such tendered and accepted Securities, times (ii) the Factor, times (iii) the Tender Offer Consideration), Holders whose Securities are accepted for purchase in the Offer will receive accrued and unpaid interest, rounded to the nearest cent, on the original US$1,000 principal amount of such Securities, from the last interest payment date up to, but not including, the Settlement Date.

Settlement

The Company anticipates that the Settlement Date for Securities validly tendered and not validly withdrawn at or prior to the Expiration Date and accepted for purchase will be September 28, 2026, the third business day after the Expiration Date. The Company's obligation to accept for purchase and to pay for the Securities validly tendered and not validly withdrawn at or prior to the Expiration Date in the Offer is subject to the satisfaction or waiver of a number of conditions described in the Offer to Purchase, including the Financing Condition and the General Conditions (each as defined in the Offer to Purchase). The Company reserves the absolute right, subject to applicable law, to: (i) waive any and all conditions to the Offer; (ii) extend or terminate the Offer; or (iii) otherwise amend the Offer in any respect. If the Offer is terminated at any time, the Securities tendered pursuant to the Offer will be promptly returned to the tendering Holders.

Dealer Managers and Tender and Information Agent

Citigroup Global Markets Inc. and Goldman Sachs & Co. LLC are acting as the dealer managers for the Offer (together, the "Dealer Managers"). The Tender and Information Agent for the Offer is Global Bondholder Services Corporation. For additional information regarding the terms of the Offer, please contact: Citigroup Global Markets Inc. at +1 (212) 723-6106 (collect) or +1 (800) 558-3745 (toll-free) or by email at ny.liabilitymanagement@citi.com, or Goldman Sachs & Co. LLC at +1 (212) 343-9668 (collect) or +1 (800) 828-3182 (toll-free) or by emailing at [email protected]. Requests for documents and questions regarding the tendering of Securities may be directed to Global Bondholder Services Corporation by telephone at (212) 430‐3774 (for banks and brokers only), (855) 654‐2015 (toll‐free) or 001‐212‐430‐3774 (international) or by email at contact@gbsc‐usa.com.

This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell with respect to any securities. The Offer is being made pursuant to the Offer to Purchase and only in such jurisdictions as is permitted under applicable law. The Offer is not being made in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.

None of the Company, the Parent Guarantor, their respective affiliates, their respective boards of directors, the Dealer Managers, the Tender and Information Agent or the trustee for the Securities is making any recommendation as to whether Holders should tender any of their Securities in connection with the Offer. Holders must make their own decision as to whether to tender any of their Securities, and, if so, the original principal amount of Securities to tender. Holders should consult their own tax, accounting, financial and legal advisers as they deem appropriate regarding the suitability of the tax, accounting, financial and legal consequences of participating or declining to participate in the Offer.

About the Company

The Company owns and operates a Coal Export Terminal located at the Port of Newcastle in the Hunter Valley region of New South Wales in Australia and is an integral part of the Australian coal export industry. The Company's facilities include rail, coal storage, ship loading facilities and associated infrastructure. The Company was formed in 2004 by its shareholders who are also customers of the Company's Terminal services. The shareholders of the Company are entities that are owned by some of the largest mining companies in the world, including BHP Group Limited, Yancoal Australia Limited, Whitehaven Coal Mining Limited, Peabody Energy Corporation, Banpu Public Company Limited (Centennial Coal) and Malabar Resources Limited, who each owns coal assets in New South Wales, Australia.

Forward-Looking Statements

This release contains forward‐looking statements. Forward‐looking statements are information of a non‐historical nature or which relate to future events and are subject to risks and uncertainties, such as the timing and results of, and other expectations regarding, the Financing Condition and the Offer. No assurance can be given that the transactions described herein will be consummated or as to the ultimate terms of any such transactions. You should not place undue reliance on these forward‐looking statements. Except as required by law or regulation, the Company does not undertake any obligation to update these forward‐looking statements.

SOURCE Newcastle Coal Infrastructure Group Pty Ltd

Share this article

Across Meta AI glasses, Instagram, and VR devices, Dolby Atmos and Dolby Vision bring greater depth, authenticity, and emotion to the experiences that matter most

SAN FRANCISCO and MENLO PARK, Calif., Sept. 23, 2026 /PRNewswire/ -- Today, Dolby Laboratories (NYSE: DLB) and Meta (NASDAQ: META) announced the expansion of Dolby experiences within the Meta ecosystem of devices and platforms. This includes new Dolby experiences coming to Meta AI glasses and Instagram.

Announced today at Meta Connect, Meta AI glasses are the first global consumer device capable of capturing audio in Dolby Atmos. Users can capture their favorite moments and share them on Instagram with their community, helping them relive those experiences and feel closer to what made them special. The news builds on the launch of Dolby Vision on Instagram last year.

"Today, creating and sharing content is part of everyday life," said John Couling, Senior Vice President of Entertainment, Dolby Laboratories. "As the lines between entertainment, creation, and social sharing get closer, people want experiences that feel more emotionally engaging. Together with Meta, we're bringing Dolby Atmos and Dolby Vision to more of the experiences people enjoy every day, making them more authentic and true to life."

Meta also announced today that its newest VR device will support Dolby Vision and Dolby Atmos, enabling more immersive experiences for movies, shows, sports, concerts, and other premium VR experiences when it launches next year.

Today's announcement reflects a broader shift in how people watch, create, and share their stories. The same technologies trusted by filmmakers, artists, and storytellers are increasingly becoming part of everyday consumption and self-expression. With Dolby, people can create, experience, and share moments in ways that feel more authentic and emotionally engaging.

The expansion also broadens Dolby's presence across one of the world's largest ecosystems for entertainment, creation, and social sharing, bringing Dolby experiences to more of the ways people connect, create, and engage every day.

Together, Dolby Atmos and Dolby Vision help people feel closer to the stories, experiences, and moments that matter most.

About Dolby:

Dolby Laboratories (NYSE: DLB) is a world leader in immersive entertainment. From movies and TV, to music, sports, gaming, and beyond, Dolby transforms the science of sight and sound into spectacular experiences for billions of people worldwide across all their favorite devices. We partner with artists, storytellers, and the brands you love to transform entertainment and digital experiences through groundbreaking innovations like Dolby Atmos, Dolby Vision, Dolby Cinema, and Dolby OptiView.

Dolby, Dolby Vision, Dolby Atmos, Dolby Cinema, Dolby OptiView and the double-D symbol are trademarks or registered trademarks of Dolby Laboratories Licensing Corporation in the United States and/or other countries. Other trademarks are the property of their respective owners.

Media Contacts:

Dolby

Cairon "Jamie" Armstrong

[email protected]

Kaitlyn Kazan

[email protected]

SOURCE Dolby Laboratories, Inc.

Share this article

- Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanced NSCLC -

- Milestone marks second Phase 3 study of setidegrasib initiated within six months -

TOKYO, Sept. 23, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, investigational KRAS G12D-targeted protein degrader, versus docetaxel in people with KRAS G12D-mutated locally advanced (unresectable) or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or after initial platinum-based chemotherapy and checkpoint inhibitor therapy (CPI).1

Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related death worldwide, with NSCLC accounting for approximately 80% of cases.2,3 Around 5% of people with NSCLC have a KRAS G12D mutation.4 Despite advances in targeted treatment for other molecularly defined forms of NSCLC, there are currently no therapies approved specifically for people with KRAS G12D-mutated NSCLC.3,5 Patients whose disease progresses on or after initial treatment currently rely on standard systemic options, such as chemotherapy.5

Setidegrasib is an investigational targeted protein degrader designed to degrade and eliminate the disease-driving KRAS G12D protein. By removing this protein, setidegrasib may help disrupt cancer cell signaling and destroy cancer cells.4 This Phase 3 study in previously treated NSCLC builds on early clinical evidence published in The New England Journal of Medicine in March 2026, which demonstrated antitumor activity and a manageable safety profile in patients with KRAS G12D-mutated solid tumors, supporting the proposed mechanism of action of setidegrasib.4

Hidenori Kitai, M.D., Ph.D., Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Japan:

"For too long, patients with KRAS G12D-mutated non-small cell lung cancer have had limited treatment options after standard therapies. This Phase 3 study represents an important step forward for the field, helping to build the evidence needed to understand whether setidegrasib could offer a potential new approach for this molecularly defined patient population."

Tadaaki Taniguchi, M.D., Ph.D., Chief Research and Development Officer, Astellas:

"The initiation of this Phase 3 study in NSCLC, our second Phase 3 study of setidegrasib within six months, reflects continued progress in its clinical development. This study will help us understand how setidegrasib's novel approach to degrading disease-driving KRAS G12D may help address unmet needs for patients with this type of NSCLC. We are grateful to the patients, investigators and study teams making this research possible."

Setidegrasib is Astellas' lead investigational targeted protein degrader. Initiation of the Phase 3 study in previously treated patients with NSCLC supports Astellas' Corporate Strategic Plan, with an ambition to initiate five or more Phase 3 or pivotal studies by fiscal year 2027. It follows the initiation of a Phase 3 study of setidegrasib in front-line pancreatic ductal adenocarcinoma (PDAC) in April 2026.6

To further inform the scientific understanding of setidegrasib and KRAS G12D-driven disease biology, Astellas will also present translational analyses from the Phase 1 study of setidegrasib in patients with KRAS G12D-mutated PDAC at the upcoming AACR Conference on Pancreatic Cancer, September 25–28, 2026.7,8 The analyses will provide further insight into mechanisms of response, resistance and potential rational combination approaches in pancreatic cancer. The findings will be featured in both a proffered oral presentation and a poster presentation.*

* Presentation details at AACR Conference on Pancreatic Cancer

Title: Integrated translational analyses of the first-generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offer rational combination strategies

Lead author: Wungki Park, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center

Details: Poster Presentation: Poster Number: B040, Date: September 27, 2026, 5:00–7:00 p.m. PT; Oral Presentation (short talk from proffered abstract): Abstract Number: PR014 B040, Date: September 28, 2026, 9:42 a.m. PT.

About the Phase 3 NSCLC Study1

The randomized, open-label Phase 3 study is evaluating setidegrasib compared with docetaxel in people with KRAS G12D-mutated locally advanced (unresectable) or metastatic NSCLC whose disease has progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy (CPI). The dual primary endpoints are progression-free survival (PFS), assessed by blinded independent central review, and overall survival (OS). Astellas plans to enroll approximately 356 patients across multiple countries into the study.

About setidegrasib4,9,10  

Setidegrasib is a novel, investigational targeted protein degrader designed to degrade and eliminate the disease-driving KRAS G12D protein. By removing this protein, setidegrasib may help disrupt cancer cell signaling and destroy cancer cells. Discovered and advanced through Astellas' in-house R&D capabilities, setidegrasib is designed to work with the cancer cell's own protein degradation machinery to bring together the KRAS G12D protein and an E3 ligase. This triggers selective degradation of the disease-driving protein, providing a distinct approach to targeting this cancer-driving mutation.

For more information on the Phase 3 study of setidegrasib in previously treated NSCLC, visit ClinicalTrials.gov and search for identifier NCT07566052. For more information about the Phase 3 study of setidegrasib in front-line PDAC, visit ClinicalTrials.gov and search for identifier NCT07409272.

The safety and efficacy of setidegrasib have not been established for the uses being considered. There is no guarantee that setidegrasib will receive regulatory approval and become commercially available for the uses being investigated.

About Astellas' Corporate Strategic Plan

Learn more at www.astellas.com/en/about/corporate-strategic-plan.

About Astellas

Astellas is a global life sciences company committed to turning innovative science into value for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions, and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

References

- ClinicalTrials.gov. U.S. National Library of Medicine. A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation. Identifier: NCT07566052. Available at: https://clinicaltrials.gov/study/NCT07566052. Last accessed September 21, 2026.

- World Health Organization. 2026. Lung cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/lung-cancer. Last accessed September 21, 2026.

- Tang Y, et al. Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential. Cancer Gene Ther. 2024;31(7):961-969. doi:10.1038/s41417-024-00778-4.

- Park W, et al. Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer. N Engl J Med. 2026;394(14):1409-1420. doi:10.1056/NEJMoa2600752.

- Reuss et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO Living Guideline. J Clin Oncol. 2026;44(7):e56-e88. doi:10.1200/JCO-25-02825.

- ClinicalTrials.gov. U.S. National Library of Medicine. A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer. Identifier: NCT07409272. Available at: https://clinicaltrials.gov/study/NCT07409272. Last accessed September 21, 2026.

- Park W. Integrated translational analyses of the first-generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offer rational combination strategies. Oral presentation at: AACR Conference on Pancreatic Cancer; September 25–28, 2026; San Diego, CA.

- Park W, et al. Integrated translational analyses of the first-generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offer rational combination strategies. Poster presented at: AACR Conference on Pancreatic Cancer; September 25–28, 2026; San Diego, CA.

- Yoshinari T, et al. Discovery of KRAS(G12D) selective degrader ASP3082. Commun Chem. 2025;8:254.

- Paz-Ares L, et al.

ANAHEIM, Calif., Sept. 23, 2026 /PRNewswire/ -- Credit Union of Southern California (CU SoCal) recently donated more than $340,000 to nonprofit organizations, educational programs, youth development initiatives, and community services across Southern California. Distributed throughout the summer, the contributions supported organizations serving Los Angeles, Orange, Riverside, and San Bernardino counties.

The donations supported a wide range of community-driven efforts focused on education, youth development, wellness, and essential services, including:

- $35,000 for Soroptimist International of Whittier and the Whittier Host Lions Club.

- $34,000 for families served by Ronald McDonald House Pasadena.

- $25,000 in combined support for Interfaith Food Center and the Welcome Home Project at Whittier Community Church.

Additional contributions supported local schools, youth organizations, educational and scholarship programs, community wellness efforts, and services for individuals and families throughout the region.

"These donations reflect CU SoCal's ongoing commitment to the communities we serve," said Dave Gunderson, President and CEO of CU SoCal. "By partnering with organizations that provide essential services and opportunities, we can extend our impact beyond financial services and help create stronger communities."

Through charitable giving, sponsorships, volunteerism, and community partnerships, CU SoCal invests in initiatives that expand opportunity and improve quality of life across Southern California.

About Credit Union of Southern California (CU SoCal)

Founded in 1954 as Whittier Area Schools Federal Credit Union, Credit Union of Southern California (CU SoCal) is a federally chartered credit union open to anyone who qualifies for Membership. Individuals may become Members through family or household relationships, employer partnerships, select educational institutions, residency or employment in Lake Havasu City, Arizona, or through a complimentary membership in a CU SoCal nonprofit partner association. CU SoCal remains a Member-owned, not-for-profit cooperative dedicated to helping Members build better lives through personalized financial services and support. CU SoCal has a superior five-star financial rating from BauerFinancial, holds more than $4 billion in assets, and serves more than 187,000 Members. For more information, visit CUSoCal.org.

SOURCE Credit Union of Southern California

Share this article

SAN FRANCISCO, Sept. 23, 2026 /PRNewswire/ -- Hagens Berman, a national law firm noted for its preeminent work in securities class action litigation, notifies investors in HDFC Bank Limited (NYSE: HDB) of a pending securities fraud class action.

- Class Period: July 17, 2023 – May 26, 2026

- Lead Plaintiff Deadline: Oct. 13, 2026

- Visit: www.hbsslaw.com/hdb

- Contact the Firm Now: [email protected] / 844-916-0895

HDFC Bank Limited (HDB) Securities Class Action Overview:

The lawsuit filed against HDFC Bank Limited ("HDFC" or the "Company"), and certain top executive officers including Chief Executive Officer Sashidhar Jagdishan and Chief Financial Officer Srinivasan Vaidyanathan, alleges violations of the federal securities laws.

Specifically, the action centers on HDFC's failure to disclose key material adverse facts regarding its business operations, financial accounting, and regulatory compliance:

- Camouflaged Marketing Payments & Covert Deposit Inducements: HDFC secretly funneled approximately Rs 45 crore (approx. $4.7 million USD) to the Maharashtra State Road Development Corporation ("MSRDC") to induce the state firm to place large deposits with the bank.

- Disguised Above-Market Interest Rates: To circumvent regulations and provide MSRDC with a 6.01% interest rate (a 2.51% markup over standard retail savings accounts), senior management devised a scheme to route the differential payments through the marketing department disguised as sponsorship contributions for a road safety awareness campaign.

- Governance and Regulatory Breaches: These covert practices violated the Reserve Bank of India's (RBI) Master Directions on interest rates and breached the bank's own internal anti-bribery and anti-corruption policies prohibiting improper inducements.

- Overstated Financials: As a result of these hidden activities, HDFC's interest income and operating expenses were overstated during the class period, rendering the Company's positive public statements and financial controls false and misleading.

Truth Begins to Unravel & Stock Price Declines:

The fraudulent scheme allegedly began to surface in stages, causing sharp drops in the market value of HDFC American Depositary Shares (ADS):

- March 18, 2026: HDFC announced the abrupt resignation of part-time Chairman and Independent Director Atanu Chakraborty, whose resignation letter stated that happenings and practices within the bank over the prior two years were "not in congruence with my personal Values and Ethics." On this news, HDFC ADS prices fell 7.28% on heavy volume.

- May 27, 2026: The Indian Express published an investigative report exposing that HDFC "camouflaged crores as marketing spend" to pay higher interest to MSRDC, revealing an internal vigilance probe implicating CEO Sashidhar Jagdishan and other top leadership. Following this disclosure, HDFC ADS fell 4.1% to close at $23.78 per share.

Hagens Berman's Investigation

"We're focused on whether HDFC's senior leadership concealed a covert scheme to funnel millions in disguised payments to induce state-firm deposits while publicly painting a picture of strong governance and compliance, as the complaint alleges," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims in the suit.

What Affected $HDB Investors Should Do

If you purchased or acquired HDFC securities between July 17, 2023, and May 26, 2026, and suffered significant financial losses, you have until October 13, 2026, to ask the court to appoint you as lead plaintiff.

To learn more about your legal options, submit your information to Hagens Berman, visit www.hbsslaw.com/hdb, call Reed Kathrein at 844-916-0895, or email [email protected].

Whistleblowers: Persons with non-public information regarding HDFC should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

Built inside a working stone shop, it is the first product of the Fabrication Cloud — homeowners to local fabricators, measured and priced before anyone visits

ST. LOUIS, Sept. 23, 2026 /PRNewswire/ -- Novaclad today released the first consumer product built on its AI-LiDAR measurement engine: a free iOS app that lets a homeowner measure their kitchen with an iPhone, price a countertop from a real catalog, and hand the job to a local fabricator in about five minutes. It is the first of its kind and the first piece of the company's Fabrication Cloud.

Custom fabrication — countertops, cabinetry, tile, millwork — is a large corner of residential construction still run on tape measures and quotes that arrive days later as one number. Novaclad's engine captures a room in three dimensions with the iPhone's LiDAR sensor, then applies a model trained on how a working shop reads a kitchen to produce a fabrication-grade takeoff and an itemized price from the shop's own price book. The fabricator receives a lead already measured and specified.

The engine was not built in a software lab. Co-founders Ryan and Audrey Brown left corporate careers in 2022 to buy Rock Creek Granite, an Imperial, Missouri, shop cutting stone since 2013 — and built Novaclad on its floor.

"We saw automation coming for the industries we came from and asked where it was needed and nobody was looking," said Ryan Brown. "Fabrication has a material-waste problem and a measurement problem. Both are software problems now."

"We didn't automate the craftsman," said Audrey Brown. "We automated the two weeks of waiting in front of him. The saw still happens. What's gone is the guesswork."

Novaclad launches in St. Louis with Rock Creek Granite as founding fabricator and places one fabricator per market through its Founder-Partner program. Countertops are the first surface; the engine is built to extend to other fabricated finishes.

The app is free; homeowners pay their fabricator for the work. It requires an iPhone 12 Pro or newer Pro model on iOS 17 or later: novaclad.com/app.

About Novaclad

Novaclad LLC is a St. Louis construction-technology company founded by Ryan and Audrey Brown, part of the Fourfold Futures venture studio. novaclad.com 

SOURCE Novaclad

Share this article